AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 34929392
Drug: Control diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control diet (23 g/d fiber)
Trial: 34929392
Drug: Minimally-fermented sugarcane
RxNorm normalized name: Sugarcane
DrugBank: Sugarcane (DB10906)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimally-fermented sugarcane bagasse (33 g/d fiber)
Trial: 34929392
Drug: Fiber combination
RxNorm normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fiber combination (sugarcane bagasse with resistant starch, ∼45 g/d fiber)
Trial: 33802283
Drug: Creatine (CRE)
DrugBank: Creatine (DB00148)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Creatine (CRE) supplementation at 0.3 g·kg−1·d−1 for seven days
Trial: 36203818
Drug: Intravenous Patient-Controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Patient-Controlled Opioid Analgesia (PCIA)
Trial: 34002265
Drug: Hexvix® TURB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hexvix® TURB with immediate ICT only (n=67, 40 mg Mitomycin)
Trial: 34002265
Drug: white-light TURB
RxNorm normalized name: Light White Mineral Oil
DrugBank: Light mineral oil (DB11579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: white-light TURB with immediate ICT followed by maintenance ICT (n=62, 20 mg Mitomycin weekly for 6 weeks, then 20 mg/month for 6 months)
Trial: 36269714
Drug: 3HR (three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3HR (three months of daily isoniazid plus rifampicin)
Trial: 36269714
Drug: 3HP (three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3HP (three months of once-weekly isoniazid plus rifapentine)
Trial: 36269714
Drug: 4R (four
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4R (four months of daily rifampicin)
Trial: 33713409
Drug: Varenicline treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varenicline treatment
Trial: 37256485
Drug: Active ophthalmic
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active ophthalmic drops (Latilactobacillus sakei)
Trial: 37256485
Drug: Placebo ophthalmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo ophthalmic drops
Trial: 37256485
Drug: Active oral
RxNorm normalized name: Factive Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active oral capsules (Latilactobacillus sakei)
Trial: 37256485
Drug: Placebo oral
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral capsules
Trial: 33660668
Drug: Nonclinic-based adolescent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonclinic-based adolescent behavioral weight control treatment delivered by YMCA coaches
Trial: 36297022
Drug: Astragalosides supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Astragalosides supplementation (4 mg per day for 7 days)
Trial: 32482519
Drug: Nifedipine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (30 mg SR orally twice daily)
Trial: 32825990
Drug: Osteopathic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osteopathic treatment (5 sessions over 8 weeks)
Trial: 34768520
Drug: Placebo (simulated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (simulated pulsed shortwave therapy)
Trial: 34218684
Drug: Repeated ivermectin
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Repeated ivermectin mass drug administrations
Trial: 34606832
Drug: 1.0% asivatrep
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0% asivatrep cream
Trial: 33631066
Drug: Tocilizumab (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocilizumab (8 mg/kg, single intravenous infusion, with a possible second dose 8 to 24 hours later)
Trial: 34147041
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg capsules of Berberis vulgaris extract, twice daily for 4 weeks
Trial: 34147041
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg of starch capsules (placebo), twice daily for 4 weeks
Trial: 32223373
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of CBT and MEDs (COMB)
Trial: 34727951
Drug: No postoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No postoperative antibiotic prophylaxis (AP)
Trial: 32947390
Drug: Umezu polyphenols
RxNorm normalized name: Pomegranate Fruit Polyphenol Extract
DrugBank: Pomegranate (DB14317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Umezu polyphenols (800 mg/day for 12 weeks)
Trial: 35215483
Drug: School-based and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: School-based and family-based interventions with monthly monitoring for two consecutive semesters
Trial: 33417728
Drug: Other WMTs
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other WMTs in cingulum, cerebral and cerebellar peduncle, internal capsule, and corpus callosum
Trial: 33865928
Drug: ENGAGE (engagement-focused
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ENGAGE (engagement-focused behavioral therapy)
Trial: 33865928
Drug: Consistent medication
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consistent medication use during behavioral therapy
Trial: 32899089
Drug: Nd:YAG laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nd:YAG laser therapy
Trial: 33344050
Drug: Topical dorzolamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical dorzolamide for 3 months
Trial: 33464334
Drug: Combined intravenous
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined intravenous thrombolysis (alteplase at 0.6 mg/kg) plus mechanical thrombectomy (n=103)
Trial: 33464334
Drug: Combined intravenous
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined intravenous thrombolysis plus mechanical thrombectomy
Trial: 35320401
Drug: Polyphenol supplement
RxNorm normalized name: Pomegranate Fruit Polyphenol Extract
DrugBank: Pomegranate (DB14317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyphenol supplement (PPS) containing black tea powder, cocoa powder, and grape juice extract
Trial: 34101212
Drug: Maternal thiamine
RxNorm normalized name: thiamine
DrugBank: Thiamine (DB00152)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maternal thiamine supplementation (10 mg/day)
Trial: 34101212
Drug: Maternal thiamine
RxNorm normalized name: thiamine
DrugBank: Thiamine (DB00152)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maternal thiamine supplementation (0 mg/day)
Trial: 34101212
Drug: Maternal thiamine
RxNorm normalized name: thiamine
DrugBank: Thiamine (DB00152)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maternal thiamine supplementation (1.2 mg/day)
Trial: 34101212
Drug: Maternal thiamine
RxNorm normalized name: thiamine
DrugBank: Thiamine (DB00152)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maternal thiamine supplementation (2.4 mg/day)
Trial: 38167019
Drug: Adalimumab monotherapy
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adalimumab monotherapy
Trial: 34158840
Drug: Panitumumab-IRDye800 at
RxNorm normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Panitumumab-IRDye800 at low (50 mg) or high (100 mg) dose
Trial: 34158840
Drug: Panitumumab-IRDye800 at
RxNorm normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Panitumumab-IRDye800 at high (100 mg) dose
Trial: 34878625
Drug: LY-CovMab 1200
RxNorm normalized name: LYS
DrugBank: Lysine (DB00123)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: LY-CovMab 1200 mg
Trial: 34878625
Drug: LY-CovMab 2400
RxNorm normalized name: LYS
DrugBank: Lysine (DB00123)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: LY-CovMab 2400 mg
Trial: 33492208
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg of lansoprazole twice daily for 16 weeks
Trial: 39187877
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy (RT)
Trial: 38824918
Drug: Hydroxyurea treatment
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyurea treatment
Trial: 33264302
Drug: Concurrent challenge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent challenge naïve subjects with B7A strain at 109 cfu
Trial: 33752794
Drug: FENIX (magnetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FENIX (magnetic sphincter augmentation device)
Trial: 34765482
Drug: MTEI-(I) at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTEI-(I) at 1 mL/kg/d (Group A)
Trial: 34765482
Drug: MTEI-(I) at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTEI-(I) at 2 mL/kg/d (Group B)
Trial: 32896089
Drug: Systematic education,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systematic education, patient diary to mark daily medicine intake, and periodic telephone reminders
Trial: 32506663
Drug: MAPC treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAPC treatment
Trial: 35595003
Drug: Pretomanid (doses:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pretomanid (doses: 50, 100, 200, 400, 600, 800, 1000 mg)
Trial: 32702837
Drug: Sihogayonggolmoryeo-tang (SYM)
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sihogayonggolmoryeo-tang (SYM) granules administered twice a day for 4 weeks
Trial: 35688623
Drug: Ultra-low-dose chest
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultra-low-dose chest CT (ULDCT)
Trial: 35963802
Drug: Olpasiran (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olpasiran (all doses)
Trial: 34518264
Drug: guselkumab maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: guselkumab maintenance dosing every 8 weeks (q8w)
Trial: 34518264
Drug: guselkumab investigational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: guselkumab investigational maintenance dosing every 16 weeks (q16w)
Trial: 616830555
Drug: Tomato juice
RxNorm normalized name: TOMATO JUICE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tomato juice (30 mg of lycopene) consumed daily for 12 weeks
Trial: 616830555
Drug: Antioxidant capsule
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant capsule (vitamin C 600 mg, vitamin E 200 mg, glutathione 300 mg) consumed daily for 12 weeks
Trial: 32462935
Drug: Improvement strategies
RxNorm normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Improvement strategies designed to boost academic success and persistence during the 6-month learning and development (L&D) phase of the program.
Trial: 34956218
Drug: Oats (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oats (80 g daily for 45 days)
Trial: 34956218
Drug: Rice (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rice (80 g daily for 45 days)
Trial: 33556319
Drug: Peginterferon lambda
RxNorm normalized name: Peginterferon lambda-1a
DrugBank: Peginterferon lambda-1a (DB14767)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peginterferon lambda 180 µg
Trial: 32916132
Drug: Dexamethasone 8
RxNorm normalized name: dexamethasone 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 8 mg (2 capsules of 4 mg) administered orally 1 hour before dental extraction
Trial: 32916132
Drug: Placebo (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2 capsules with same characteristics as dexamethasone) administered orally 1 hour before dental extraction
Trial: 33724251
Drug: Dasotraline 6
RxNorm normalized name: Dasotraline
DrugBank: Dasotraline (DB12305)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dasotraline 6 mg/day
Trial: 32980184
Drug: Placebo (inactive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (inactive control vehicle, infused over 30 min, once daily for 7 days)
Trial: 35429465
Drug: 12-month oral
RxNorm normalized name: moth bean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12-month oral itraconazole
Trial: 34699671
Drug: Topical tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical tranexamic acid after dermapen microneedling
Trial: 34529341
Drug: Topical minoxidil
RxNorm normalized name: MINOXIDIL 50 mg in 1 mL TOPICAL SOLUTION [Stafenit Hair Regrowth Treatment Topical Minoxidil]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical minoxidil 2% solution
Trial: 34787858
Drug: Routine intravenous
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine intravenous injection
Trial: 33012017
Drug: Photobiomodulation and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photobiomodulation and topical clobetasol 0.05%
Trial: 34103345
Drug: Avoiding antiplatelet
RxNorm normalized name: simethicone
DrugBank: Simethicone (DB09512)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avoiding antiplatelet therapy
Trial: 37811523
Drug: Tadalafil (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil (20 mg)
Trial: 33248743
Drug: Training clinicians
RxNorm normalized name: sulfur
DrugBank: Octasulfur (DB09353)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Training clinicians to increase TUD treatment
Trial: 34253180
Drug: Medication usage
RxNorm normalized name: SAGE
DrugBank: Sage (DB10982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication usage
Trial: 35457632
Drug: Moderate-intensity physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate-intensity physical activity program (twice a week for 8 weeks)
Trial: 32421444
Drug: Standard anthracycline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard anthracycline plus ifosfamide neoadjuvant chemotherapy (A+I)
Trial: 33950073
Drug: Motivational interviewing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motivational interviewing associated with cognitive behavioral therapy (CBT)
Trial: 34302893
Drug: High-sensitivity cardiac
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-sensitivity cardiac troponin T (hs-cTnT) levels before treatment
Trial: 33587659
Drug: Higher-dose edoxaban
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher-dose edoxaban regimen
Trial: 32873667
Drug: Pioglitazone 30
RxNorm normalized name: pioglitazone 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone 30 mg per day
Trial: 32250066
Drug: 1-day preparation
RxNorm normalized name: Caviar Preparation
DrugBank: Caviar, unspecified (DB14241)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-day preparation using PEG 3350 (4 g/kg/day) + bisacodyl
Trial: 35554590
Drug: Suvorexant (initially
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suvorexant (initially 10 mg, increased to 20 mg after 1 week if tolerated)
Trial: 32223585
Drug: Fascial therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fascial therapy (three 45‐min sessions over a 3‐week period)
Trial: 33276518
Drug: Oral resveratrol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral resveratrol supplementation for 4 days
Trial: 33276518
Drug: Oral resveratrol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral resveratrol supplementation
Trial: 33475318
Drug: Combination model
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination model
Trial: 34285713
Drug: COC with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COC with GR blockade (mifepristone; 80.0 mg/kg; po)
Trial: 34285713
Drug: COC with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COC with MR blockade (spironolactone; 0.25 mg/kg; po)
Trial: 34285713
Drug: COC (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COC (1.0 μg ethinylestradiol and 5.0 μg levonorgestrel; po)
Trial: 35101832
Drug: Placebo (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (standard treatment)
Trial: 33025883
Drug: Caffeinated coffee
RxNorm normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeinated coffee (CC) in non-hyperuricaemic participants
Trial: 36251165
Drug: Rencofilstat (RCF)
RxNorm normalized name: Rencofilstat
DrugBank: Rencofilstat (DB18246)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rencofilstat (RCF) 225-mg soft gelatin capsules with high-fat meal
Trial: 32415365
Drug: Intravenous tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous tranexamic acid (IV‐TXA)
Trial: 34022863
Drug: Non-opioid postoperative
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-opioid postoperative protocol (standardized non-opioid analgesic prescription, limited rescue opioid prescription, patient education infographic)
Trial: 34022863
Drug: Current standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current standard of care (treating surgeons’ pre-trial postoperative analgesic regimen)
Trial: 32808504
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy followed by interval debulking surgery (NACT‐IDS) with 3 cycles of NACT and subsequently 3 cycles of adjuvant chemotherapy
Trial: 32991207
Drug: Aquatic Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aquatic Therapy Group (ATG)
Trial: 34049943
Drug: Tezepelumab (700
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tezepelumab (700 mg intravenously at 4-week intervals for 12 weeks)
Trial: 33075844
Drug: 81-mg daily
RxNorm normalized name: glecaprevir
DrugBank: Glecaprevir (DB13879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 81-mg daily aspirin
Trial: 34336070
Drug: Conventional rehabilitation
RxNorm normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional rehabilitation treatment
Trial: 32710457
Drug: Genotype-guided warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genotype-guided warfarin anticoagulation
Trial: 38413986
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (500 mg/day)
Trial: 34275457
Drug: Multicomponent intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multicomponent intervention including systematic medication review
Trial: 35445719
Drug: sarilumab 150
RxNorm normalized name: SARILUMAB 150MG/1.14ML INJ SYR 1.14ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sarilumab 150 mg
Trial: 37471590
Drug: sarilumab 200
RxNorm normalized name: SARILUMAB 200MG/1.14ML INJ SYR 1.14ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sarilumab 200 mg
Trial: 36426355
Drug: Probiotics (Bifidobacterium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotics (Bifidobacterium Tetragenous viable Bacteria Tablets)
Trial: 35985981
Drug: Androgen Deprivation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen Deprivation Therapy with Docetaxel
Trial: 35985981
Drug: Androgen Deprivation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen Deprivation Therapy without Docetaxel
Trial: 32424568
Drug: Monitor group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monitor group (MG)
Trial: 33759678
Drug: Supplement (SUPP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplement (SUPP) - 200-mL carton of juice-based emulsion containing 3000 mg LC n-3 PUFA (1500 mg DHA and 1500 mg EPA), 8 g whey protein isolate, 400 IU vitamin D3, 150 mg resveratrol
Trial: 33759678
Drug: Supplement (SUPP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplement (SUPP)
Trial: 32122216
Drug: Prasugrel 10
RxNorm normalized name: prasugrel 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel 10 mg once a day
Trial: 37981893
Drug: Low-dose computed
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose computed tomography (LDCT) screening
Trial: 32993653
Drug: Echium amoenum
RxNorm normalized name: Echium plantagineum seed oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Echium amoenum (EA) 450 mg capsules per day (three times a day) for two consecutive cycles
Trial: 33028427
Drug: Flaxseed (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flaxseed (20 g/d)
Trial: 33028427
Drug: Puffed wheat
RxNorm normalized name: WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Puffed wheat (25 g/d)
Trial: 32773268
Drug: Intravenous steroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous steroids only
Trial: 32773268
Drug: Intravenous and
RxNorm normalized name: immune globulin intravenous and subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous and periarticular steroids (IVPAS)
Trial: 39311825
Drug: Ketamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine infusion